2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2021
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal 2021, 42: 4947-4960. PMID: 34293101, PMCID: PMC8691807, DOI: 10.1093/eurheartj/ehab420.Peer-Reviewed Original ResearchConceptsNADPH oxidase activityMyocardial redoxHuman cardiomyocytesNOS couplingAtrial tissueSodium-glucose cotransporter 2 inhibitorsMyocardial NADPH oxidase activityRight atrial appendage biopsiesNitric oxide synthase uncouplingCotransporter 2 inhibitorsEffects of canagliflozinHeart failure patientsBeneficial cardiac effectsExpression of inflammationRecent clinical trialsAMP kinaseHuman atrial tissueOxidase activityPrimary human cardiomyocytesAnti-apoptotic effectsTetrahydrobiopterin bioavailabilityCardiovascular outcomesCardiac effectsFailure patientsCardiac surgery
2020
Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
Kondo H, Akoumianakis I, Akawi N, Kotanidis C, Antonopoulos A, Carena M, Badi I, Oikonomou E, Reus E, Krasopoulos G, Chuaiphichai S, Shirodaria C, Channon K, Casadei B, Antoniades C. Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition. European Heart Journal 2020, 41: ehaa946.3351. DOI: 10.1093/ehjci/ehaa946.3351.Peer-Reviewed Original ResearchHuman primary cardiomyocytesNitric oxide synthaseMyocardial biopsiesHuman myocardial biopsiesMyocardial redoxOxide synthaseHuman myocardiumSodium-glucose cotransporter 2 inhibitorsMyocardial NADPH oxidase activityRight atrial appendage biopsiesGlucose cotransporter 2 inhibitorsUncoupled nitric oxide synthaseSGLT1/SGLT2 inhibitorsCotransporter 2 inhibitorsEffects of canagliflozinHeart failure patientsPro-fibrotic markersRecent clinical trialsBritish Heart FoundationNADPH oxidase subunitsBioavailability of tetrahydrobiopterinNADPH oxidase activityAnti-apoptotic effectsDirect effectBasal O2